3,788 reports of this reaction
2.1% of all DIAZEPAM ORAL SOLUTION (CONCENTRATE) reports
#5 most reported adverse reaction
COMPLETED SUICIDE is the #5 most commonly reported adverse reaction for DIAZEPAM ORAL SOLUTION (CONCENTRATE), manufactured by Alembic Pharmaceuticals Inc.. There are 3,788 FDA adverse event reports linking DIAZEPAM ORAL SOLUTION (CONCENTRATE) to COMPLETED SUICIDE. This represents approximately 2.1% of all 177,526 adverse event reports for this drug.
Patients taking DIAZEPAM ORAL SOLUTION (CONCENTRATE) who experience completed suicide should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COMPLETED SUICIDE is a less commonly reported adverse event for DIAZEPAM ORAL SOLUTION (CONCENTRATE), but still significant enough to appear in the safety profile.
In addition to completed suicide, the following adverse reactions have been reported for DIAZEPAM ORAL SOLUTION (CONCENTRATE):
The following drugs have also been linked to completed suicide in FDA adverse event reports:
COMPLETED SUICIDE has been reported as an adverse event in 3,788 FDA reports for DIAZEPAM ORAL SOLUTION (CONCENTRATE). This does not prove causation, but indicates an association observed in post-market surveillance data.
COMPLETED SUICIDE accounts for approximately 2.1% of all adverse event reports for DIAZEPAM ORAL SOLUTION (CONCENTRATE), making it a notable side effect.
If you experience completed suicide while taking DIAZEPAM ORAL SOLUTION (CONCENTRATE), contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.